326 related articles for article (PubMed ID: 34801353)
1. Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer.
Schneeweiss A; Michel LL; Möbus V; Tesch H; Klare P; Hahnen E; Denkert C; Kast K; Pohl-Rescigno E; Hanusch C; Link T; Untch M; Jackisch C; Blohmer JU; Fasching PA; Solbach C; Schmutzler RK; Huober J; Rhiem K; Nekljudova V; Lübbe K; Loibl S;
Eur J Cancer; 2022 Jan; 160():100-111. PubMed ID: 34801353
[TBL] [Abstract][Full Text] [Related]
2. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial.
Schneeweiss A; Möbus V; Tesch H; Hanusch C; Denkert C; Lübbe K; Huober J; Klare P; Kümmel S; Untch M; Kast K; Jackisch C; Thomalla J; Ingold-Heppner B; Blohmer JU; Rezai M; Frank M; Engels K; Rhiem K; Fasching PA; Nekljudova V; von Minckwitz G; Loibl S
Eur J Cancer; 2019 Jan; 106():181-192. PubMed ID: 30528802
[TBL] [Abstract][Full Text] [Related]
3. German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients.
Möbus V; von Minckwitz G; Jackisch C; Lück HJ; Schneeweiss A; Tesch H; Elling D; Harbeck N; Conrad B; Fehm T; Huober J; Müller V; Bauerfeind I; du Bois A; Loibl S; Nekljudova V; Untch M; Thomssen C;
Ann Oncol; 2017 Aug; 28(8):1803-1810. PubMed ID: 28459941
[TBL] [Abstract][Full Text] [Related]
4. Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial.
Möbus V; Jackisch C; Lück HJ; du Bois A; Thomssen C; Kuhn W; Nitz U; Schneeweiss A; Huober J; Harbeck N; von Minckwitz G; Runnebaum IB; Hinke A; Konecny GE; Untch M; Kurbacher C;
Ann Oncol; 2018 Jan; 29(1):178-185. PubMed ID: 29069370
[TBL] [Abstract][Full Text] [Related]
5. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
Loibl S; Weber KE; Timms KM; Elkin EP; Hahnen E; Fasching PA; Lederer B; Denkert C; Schneeweiss A; Braun S; Salat CT; Rezai M; Blohmer JU; Zahm DM; Jackisch C; Gerber B; Klare P; Kümmel S; Schem C; Paepke S; Schmutzler R; Rhiem K; Penn S; Reid J; Nekljudova V; Hartman AR; von Minckwitz G; Untch M
Ann Oncol; 2018 Dec; 29(12):2341-2347. PubMed ID: 30335131
[TBL] [Abstract][Full Text] [Related]
6. Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial.
Zhang P; Yin Y; Mo H; Zhang B; Wang X; Li Q; Yuan P; Wang J; Zheng S; Cai R; Ma F; Fan Y; Xu B
Oncotarget; 2016 Sep; 7(37):60647-60656. PubMed ID: 27447966
[TBL] [Abstract][Full Text] [Related]
7. Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial.
Gluz O; Kuemmel S; Nitz U; Braun M; Lüdtke-Heckenkamp K; von Schumann R; Darsow M; Forstbauer H; Potenberg J; Uleer C; Grischke EM; Aktas B; Schumacher C; Zu Eulenburg C; Kates R; Jóźwiak K; Graeser M; Wuerstlein R; Baehner R; Christgen M; Kreipe HH; Harbeck N
Ann Oncol; 2023 Jun; 34(6):531-542. PubMed ID: 37062416
[TBL] [Abstract][Full Text] [Related]
8. Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer: A Secondary Analysis of the GeparOcto Randomized Clinical Trial.
Pohl-Rescigno E; Hauke J; Loibl S; Möbus V; Denkert C; Fasching PA; Kayali M; Ernst C; Weber-Lassalle N; Hanusch C; Tesch H; Müller V; Altmüller J; Thiele H; Untch M; Lübbe K; Nürnberg P; Rhiem K; Furlanetto J; Lederer B; Jackisch C; Nekljudova V; Schmutzler RK; Schneeweiss A; Hahnen E
JAMA Oncol; 2020 May; 6(5):744-748. PubMed ID: 32163106
[TBL] [Abstract][Full Text] [Related]
9. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
Nitz U; Gluz O; Graeser M; Christgen M; Kuemmel S; Grischke EM; Braun M; Augustin D; Potenberg J; Krauss K; Schumacher C; Forstbauer H; Reimer T; Stefek A; Fischer HH; Pelz E; Zu Eulenburg C; Kates R; Wuerstlein R; Kreipe HH; Harbeck N;
Lancet Oncol; 2022 May; 23(5):625-635. PubMed ID: 35405088
[TBL] [Abstract][Full Text] [Related]
10. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE).
Meyer-Wilmes P; Huober J; Untch M; Blohmer JU; Janni W; Denkert C; Klare P; Link T; Rhiem K; Bayer C; Reinisch M; Bjelic-Radisic V; Zahm DM; Hanusch C; Solbach C; Heinrich G; Hartkopf AD; Schneeweiss A; Fasching P; Filmann N; Nekljudova V; Holtschmidt J; Stickeler E; Loibl S
ESMO Open; 2024 May; 9(5):103009. PubMed ID: 38663168
[TBL] [Abstract][Full Text] [Related]
12. Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience.
Singh JC; Mamtani A; Barrio A; Morrow M; Sugarman S; Jones LW; Yu AF; Argolo D; Smyth LM; Modi S; Schweber S; Boafo C; Patil S; Norton L; Baselga J; Hudis CA; Dang C
Oncologist; 2017 Feb; 22(2):139-143. PubMed ID: 28167568
[TBL] [Abstract][Full Text] [Related]
13. Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2).
Möbus V; Lück HJ; Ladda E; Klare P; Schmidt M; Schneeweiss A; Grischke EM; Wachsmann G; Forstbauer H; Untch M; Marmé F; Blohmer JU; Jackisch C; Huober J; Stickeler E; Reinisch M; Link T; Sinn BV; Janni W; Denkert C; Furlanetto J; Engels K; Solbach C; Schmatloch S; Rey J; Burchardi N; Loibl S;
Eur J Cancer; 2021 Oct; 156():138-148. PubMed ID: 34450552
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response.
Loibl S; Schneeweiss A; Huober J; Braun M; Rey J; Blohmer JU; Furlanetto J; Zahm DM; Hanusch C; Thomalla J; Jackisch C; Staib P; Link T; Rhiem K; Solbach C; Fasching PA; Nekljudova V; Denkert C; Untch M;
Ann Oncol; 2022 Nov; 33(11):1149-1158. PubMed ID: 35961599
[TBL] [Abstract][Full Text] [Related]
15. Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial.
Blohmer JU; Link T; Reinisch M; Just M; Untch M; Stötzer O; Fasching PA; Schneeweiss A; Wimberger P; Seiler S; Huober J; Thill M; Jackisch C; Rhiem K; Solbach C; Hanusch C; Seither F; Denkert C; Engels K; Nekljudova V; Loibl S;
JAMA Oncol; 2022 Jul; 8(7):1010-1018. PubMed ID: 35588050
[TBL] [Abstract][Full Text] [Related]
16. Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up.
Zheng F; Du F; Wang W; Wang Y; Li M; Zhao J; Wang X; Yue J; Wang J; Yang Z; Cai R; Ma F; Fan Y; Li Q; Zhang P; Xu B; Yuan P
Breast Cancer Res Treat; 2022 Jan; 191(1):97-105. PubMed ID: 34648118
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab for Early Triple-Negative Breast Cancer.
Schmid P; Cortes J; Pusztai L; McArthur H; Kümmel S; Bergh J; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Foukakis T; Fasching PA; Cardoso F; Untch M; Jia L; Karantza V; Zhao J; Aktan G; Dent R; O'Shaughnessy J;
N Engl J Med; 2020 Feb; 382(9):810-821. PubMed ID: 32101663
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study).
Fasching PA; Link T; Hauke J; Seither F; Jackisch C; Klare P; Schmatloch S; Hanusch C; Huober J; Stefek A; Seiler S; Schmitt WD; Uleer C; Doering G; Rhiem K; Schneeweiss A; Engels K; Denkert C; Schmutzler RK; Hahnen E; Untch M; Burchardi N; Blohmer JU; Loibl S;
Ann Oncol; 2021 Jan; 32(1):49-57. PubMed ID: 33098995
[TBL] [Abstract][Full Text] [Related]
19. Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.
Baselga J; Manikhas A; Cortés J; Llombart A; Roman L; Semiglazov VF; Byakhov M; Lokanatha D; Forenza S; Goldfarb RH; Matera J; Azarnia N; Hudis CA; Rozencweig M
Ann Oncol; 2014 Mar; 25(3):592-598. PubMed ID: 24401928
[TBL] [Abstract][Full Text] [Related]
20. NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto.
Untch M; Jackisch C; Schneeweiss A; Schmatloch S; Aktas B; Denkert C; Schem C; Wiebringhaus H; Kümmel S; Warm M; Fasching PA; Just M; Hanusch C; Hackmann J; Blohmer JU; Rhiem K; Schmitt WD; Furlanetto J; Gerber B; Huober J; Nekljudova V; von Minckwitz G; Loibl S
J Clin Oncol; 2019 Sep; 37(25):2226-2234. PubMed ID: 31082269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
